

SUPPLEMENTARY TABLE S5. NUMBER OF REPORTED CELL AND TISSUE-ENGINEERED THERAPY TREATMENTS IN EUROPE IN 2017 AND [2016] SORTED BY DELIVERY MODE

<i>Indications</i>	<i>Cell delivery mode</i>			
	<i>i.v. or i.a</i>	<i>Intraorgan</i>		
		<i>Suspension</i>	<i>Gel</i>	<i>Membrane/scaffold</i>
Cardiovascular				
Peripheral artery disease	4 [7]	2 [6]		
Cardiomyopathy	3 [2]	1 [14]		
Heart failure	10 [11]	4 [102]		1 [3]
Myocardial ischemia	2 [2]	54 [0]		7 [0]
Decubitus+leg ulcers			[17]	10 [62]
Other	2 [0]	3 [102]		[94]
Musculoskeletal/rheumatological				
Bone repair (maxillofacial)		1 [2]	0 [3]	0 [8]
Bone repair (orthopedics)		8 [12]		7 [56]
Osteogenesis imperfecta	2 [0]			
Cartilage repair (maxillofacial)		[35]		
Cartilage repair (orthopedics)	26 [37]	278 [43]	15 [10]	793 [184]
Muscle repair		3 [24]	9 [5]	
Tendon/ligament	10 [20]	26 [17]		
Reconstructive surgery/tissue enhancement		11 [44]		0 [4]
Scleroderma	7 [7]	1 [0]		
Arthritis	2 [10]	20 [539]		
Other	5 [2]	27 [87]		0 [2]
Neurological				
Multiple sclerosis	41 [61]	3 [2]		
Amyotrophic lateral sclerosis	28 [19]	24 [0]		0 [1]
Parkinson's		0 [1]		
Peripheral nerve regeneration (trauma)		0 [9]		
Other	10 [5]	69 [59]		
Gastrointestinal				
Crohn's disease		0 [17]		
Liver insufficiency	0 [13]	2 [3]		
Hematology/oncology				
Hematological malignancies	1710 [1581]	8 [3]		
Solid tumor	80 [69]	10 [48]		
Miscellaneous				
Skin reconstruction—burns		7 [322]	0 [6]	37 [6]
Cornea repair				19 [20]
Diabetes	18 [14]	3 [0]		
Other	21 [43]	291 [595]	0 [20]	0 [11]
Total	1981 [1903]	856 [2086]	24 [61]	874 [451]

i.a., intra-arterial; i.v., intravenous.